CCR1 and brain neoplasm: Furthermore, data from CC-90010-GBM-001 have demonstrated that trotabresib at a dose of 30 mg results in sufficient exposures to drive BBB penetration, with the study showing measurable concentrations and modulation of pharmacodynamic markers of target engagement in brain tumor tissue.22 Importantly, the trotabresib 30 mg 4 days on/24 days off dosing schedule was sufficient to induce BET inhibition, as determined by blood CCR1 expression, while maintaining platelet nadir >100,000/mm3.